ACADIA PHARMACEUTICALS INC. Increase (Decrease) in Restricted Cash for Operating Activities
ACADIA PHARMACEUTICALS INC. (ACAD) reported Increase (Decrease) in Restricted Cash for Operating Activities of $100.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities · last filed 2018-02-27
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-12-31 was $0.00.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-09-30 was $0.00.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-06-30 was $0.00.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for the quarter ending 2017-03-31 was $100.00K.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for fiscal 2017 was $100.00K, a 95.00% decline from fiscal 2016.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for fiscal 2016 was $2.00M, a 433.33% increase from fiscal 2015.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in restricted cash for operating activities for fiscal 2015 was $375.00K.
| Period end | Increase (Decrease) in Restricted Cash for Operating Activities 3 month | Increase (Decrease) in Restricted Cash for Operating Activities 6 month | Increase (Decrease) in Restricted Cash for Operating Activities 9 month | Increase (Decrease) in Restricted Cash for Operating Activities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $0.00 derived: sum of 2 quarters · filed 2018-02-27 | $0.00 derived: sum of 3 quarters · filed 2018-02-27 | $100.00K 10-K · filed 2018-02-27 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 derived: sum of 2 quarters · filed 2017-11-07 | $100.00K 10-Q · filed 2017-11-07 | $100.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $100.00K 10-Q · filed 2017-08-08 | $100.00K derived: sum of 3 quarters · filed 2018-02-27 | $100.00K derived: sum of 4 quarters · filed 2018-02-27 |
| 2017-03-31 | $100.00K 10-Q · filed 2017-05-09 | $100.00K derived: sum of 2 quarters · filed 2018-02-27 | $100.00K derived: sum of 3 quarters · filed 2018-02-27 | |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $0.00 derived: sum of 2 quarters · filed 2018-02-27 | $2.00M 10-K · filed 2018-02-27 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $2.00M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $2.00M 10-Q · filed 2017-08-08 | |||
| 2015-12-31 | $375.00K 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |